1. Introduction {#sec1-pharmacy-08-00039}
===============

As of 2019, people older than 65 years represent 20% of the French population \[[@B1-pharmacy-08-00039]\]. Approximately 10% of subjects \>75 years old live in residential care homes for the elderly (nursing homes), and this goes up to 30% for subjects \>90 years old \[[@B2-pharmacy-08-00039]\]. Long-term care expenses for nursing home residents reached almost 10 million euros in France in 2017 \[[@B3-pharmacy-08-00039]\]. According to the Caisse Nationale de Solidarité pour l'Autonomie (CNSA; French national funding agency for the elderly and handicapped), 37% of nonhospital care expenses recorded in 2017 for nursing home residents relate to the purchase of medications \[[@B4-pharmacy-08-00039]\].

Polymedication and potentially inappropriate medications (PIM) are risk factors for drug-induced iatrogenesis \[[@B5-pharmacy-08-00039]\]. Despite national and international recommendations advising the elimination of PIM in the elderly, the prevalence of their prescription remains high \[[@B6-pharmacy-08-00039]\]. PIM can cause iatrogenic events with serious clinical and economic consequences \[[@B7-pharmacy-08-00039],[@B8-pharmacy-08-00039]\], even though these are potentially preventable. The process of improving the quality of medication management helps to achieve a double objective: reducing iatrogenic events and their consequences for elderly people's health and reducing healthcare costs \[[@B9-pharmacy-08-00039]\].

The Occitanie region is the second largest region in France. The region's population is on average older than the French population. The aging index (ratio of the number of inhabitants aged 65 or over per 100 young people under 20) is the fourth highest in France: it is 89.1, versus a national average of 72.2 \[[@B10-pharmacy-08-00039]\]. Various efforts have been made in the region to improve the care of the elderly. In 2010, the IQUARE project (Impact of QUAlity control on the development of practices and the functional decline of nursing home REsidents) was implemented in the region to optimize the quality of care practices in nursing homes \[[@B11-pharmacy-08-00039],[@B12-pharmacy-08-00039]\].

The main objective of our study is to determine the direct costs incurred by PIM in nursing homes. The secondary objective is to measure the potential impact of the proposed deprescription of PIM, in terms of medication costs.

2. Method {#sec2-pharmacy-08-00039}
=========

2.1. Study Population {#sec2dot1-pharmacy-08-00039}
---------------------

We carried out a retrospective study on 19 nursing homes in the West Occitanie region. We only included nursing homes that have a dispensary in order to ensure we were only looking at establishments using medications with a price fixed at the national level. Nursing homes with in-house pharmacies were excluded from this study.

For each resident, the following socio-demographic and clinical data were collected:-Age;-Sex;-Iso-Resource Group (IRG): IRG measures the degree of independence on a scale of 1 to 6 for an elderly person: IRG 1 corresponds to total dependency;-Medical history and comorbidities;-Long-term prescriptions and their dosages. We have excluded prescriptions involving medications indicated in acute pathologies (antibiotic therapies, etc.). We have also excluded adjunctive drugs (e.g., analgesic, antifungal), topical medications (creams, eye drops), laxatives, and all nonreimbursed drugs.

Using the medical histories and comorbidities, we were able to work out the Charlson index \[[@B13-pharmacy-08-00039]\]. Widely used in clinical trials, the Charlson index is a tool for predicting short-term mortality in elderly patients. This score is calculated by adding the different weights assigned to 19 medical conditions \[[@B14-pharmacy-08-00039]\]. Adjustment with the patients' ages results in a weighted score which varies between 1 (for patients aged 50 to 59 years) to 5 (for subjects between 90 and 99 years). Patients with a Charlson score ≥ 5 have more comorbidities and have an 85% risk of mortality at 1 year. This percentage decreases to 12% for patients with a Charlson score of zero \[[@B15-pharmacy-08-00039]\].

2.2. Identification of Potentially Inappropriate Medications {#sec2dot2-pharmacy-08-00039}
------------------------------------------------------------

We have used the European EU(7) PIM list \[[@B16-pharmacy-08-00039]\] to identify PIM. Medications are considered potentially inappropriate when their risk/benefit ratio is unfavorable and there is a safer alternative available, or when their efficacy has not been proven in a given indication \[[@B16-pharmacy-08-00039]\]. We then carried out a simulated substitution of the PIM with alternatives suggested on the EU(7) PIM list.

However, we did not consider prescriptions that included a PIM in the following two cases:-Serious pathologies (epilepsy, Parkinson, heart failure, diabetes, etc.) where it is necessary to have the patient's exhaustive medical file to propose suitable modifications to prescriptions.-When the EU(7) PIM list does not suggest an alternative as a substitution, we left the PIM as given on the prescription (for example: amiodarone).

[Appendix A](#app1-pharmacy-08-00039){ref-type="app"} shows the PIM alternatives proposed during our prescription analysis.

2.3. Cost of Medications {#sec2dot3-pharmacy-08-00039}
------------------------

We calculated the daily cost of medications (unit price of the medication adjusted according to the dosage) and included only medications reimbursed by health insurance, the price of which is fixed at the national level. This price is available on the website of the national database of medications \[[@B17-pharmacy-08-00039]\].

2.4. Statistical Analysis {#sec2dot4-pharmacy-08-00039}
-------------------------

We carried out a descriptive analysis of the sociodemographic and clinical variables of the patients. For quantitative variables, the results were presented in the form of mean ± standard deviation (SD). For categorical variables, we calculated the total numbers and percentages.

The tests used were chosen according to the nature of the variables and the size of the samples: the Mann--Whitney Wilcoxon test and the Kruskal--Wallis test for quantitative variables, and the chi-squared test for qualitative variables.

Finally, using a linear regression model we analyzed the correlation between the cost of prescriptions with at least one PIM and the following four variables: sex, IRG, Charlson score and number of PIM per prescription

Statistical tests were performed using a two-sided alpha significance level of 5%. Data were analyzed using SAS software version 9.4 (SAS Institute, SAS Campus Drive, Cary, NC, USA).

3. Results {#sec3-pharmacy-08-00039}
==========

3.1. Study Population {#sec3dot1-pharmacy-08-00039}
---------------------

A total of 1240 residents were included in our study. After excluding the medications prescribed for an acute condition and those that are not reimbursed, 7768 prescriptions were analyzed ([Figure 1](#pharmacy-08-00039-f001){ref-type="fig"}). The average age of the population was 87.8 ± 7.6 years: 42.9% (n = 532) of the residents are dependent (IRG 1--2) and only 4.6% (n = 57) of them are independent (IRG 5--6) ([Table 1](#pharmacy-08-00039-t001){ref-type="table"}). About 79% (n = 969) of residents have a Charlson score ≥ 5 with an average number of pathologies of 3.9 ± 1.9 (range: 0--13) most frequently comprising hypertension (17.2%, n = 462) and dementia (14.1%, n = 380) ([Table 2](#pharmacy-08-00039-t002){ref-type="table"}). The average number of individual medications is 6.2 (±2.9) and 58% (n = 721) of residents take ≥5 medications.

3.2. PIM Prescription {#sec3dot2-pharmacy-08-00039}
---------------------

According to the EU(7) PIM list, 25% (n = 1956) of prescriptions are considered inappropriate ([Figure 2](#pharmacy-08-00039-f002){ref-type="fig"}): 77% of residents (n = 959) have at least one PIM and the average number of PIMs per resident is 2.04 ± 1.17 (min: 1, max: 9). The percent of patients with more than five drugs is significantly higher when prescriptions contained at least one PIM than those without PIM (*p* \< 0.0001).

3.3. Cost of Prescriptions and Cost of PIM {#sec3dot3-pharmacy-08-00039}
------------------------------------------

The average daily cost of all prescriptions for residents is 2.61 euros. We compared the overall cost of prescriptions without PIM estimated at €1.9 ± 2.7 with that of prescriptions with at least one PIM estimated at €2.81 ± 2.25, showing a statistically significant difference (*p* \<0.0001). Furthermore, in prescriptions with at least one PIM, 21% of the cost is incurred by the PIM. The average cost of PIM is €0.58 ± 0.51 per prescription/per day.

Based on a linear regression model, we analyzed the correlation between the cost of prescriptions with at least one PIM and the following four variables: gender, IRG, Charlson score and number of PIM per prescription. Only the number of PIM per prescription is significantly associated with the cost of prescriptions (R^2^ = 0.05, *p* \< 0.0001). However, since the variable R^2^ is very small, the number of PIM per prescription is not sufficient in itself to explain the variability of the cost of prescriptions with PIM.

3.4. Cost of Prescriptions after Substitution of PIM {#sec3dot4-pharmacy-08-00039}
----------------------------------------------------

To analyze the impact of deprescription of PIM on the cost of prescriptions, we substituted the PIM with alternative drugs according to the EU(7) PIM list ([Appendix A](#app1-pharmacy-08-00039){ref-type="app"}). Alternative drugs were significantly less expensive than PIM: the average cost of these alternatives was €0.48 ± 0.48, compared to €0.58 ± 0.51 for PIM (*p* \< 0.0001) ([Figure 3](#pharmacy-08-00039-f003){ref-type="fig"}). Consequently, substituted prescriptions cost significantly less than prescriptions with at least one PIM (*p* \< 0.0001) ([Figure 3](#pharmacy-08-00039-f003){ref-type="fig"}). The deprescription of PIM and their substitution with more suitable alternative drugs ensures a significant saving on the daily cost of prescriptions (i.e., €0.12 per day per prescription).

4. Discussion {#sec4-pharmacy-08-00039}
=============

According to the World Health Organization (WHO), polymedication accounts for 4% of avoidable costs caused by the nonoptimal use of medications \[[@B18-pharmacy-08-00039]\]. Prescription of potentially inappropriate medications is linked to polymedication \[[@B19-pharmacy-08-00039]\]. In France, the average cost of a prescription is 71 euros for people over 65 \[[@B20-pharmacy-08-00039]\].

In 2017, 728,000 elderly people in France were living in nursing homes \[[@B20-pharmacy-08-00039]\]. According to our results, 78% of residents are exposed to PIM, which corresponds to 567,840 residents exposed to PIM in France. If in this study the prescription of PIM and their substitution with more appropriate medications saves 0.12 euros per resident per day, this approach would save more than 25 million euros per year on the national level.

Different studies have looked at the cost of PIM among elderly people in hospitals and as outpatients \[[@B21-pharmacy-08-00039],[@B22-pharmacy-08-00039],[@B23-pharmacy-08-00039]\]. However, very few studies have evaluated the cost of PIM in nursing homes \[[@B22-pharmacy-08-00039]\]. In the same region, in Occitanie, a recent study carried out at Toulouse University Hospital on 365 elderly hospitalized patients shows that 50% of patients take at least one PIM. This percentage is relatively lower than that of the residents of nursing homes in our study (77%). A study comparable to ours was carried out in 2016 in another French region (Alsace) and shows that PIM are prescribed in 74% of residents \[[@B22-pharmacy-08-00039]\]. These studies therefore show a difference in the profile of medication use among the elderly living in their own home and those in nursing homes.

The proper use of medication among elderly people living at home or in nursing homes allows for a reduction in prescriptions of PIM as well as in the cost of the prescription. In our study, the average daily cost of PIM is €0.58 ± 0.51 or 21% of the average cost of prescriptions. This percentage is comparable to the result from hospitals (20%) but significantly higher than the Alsace study (11.6%) for a comparable average daily cost (€0.49 ± 0.76). Alsace has not been part of the PAERPA experiment (Elderly People At Risk of Loss of Autonomy), so we could not compare the indicators of polypharmacy and inappropriate prescription \[[@B24-pharmacy-08-00039]\] between the two regions. The deprescription of PIM and their substitution results in a significant saving on the cost of prescriptions. According to our results, we can estimate a potential saving of 0.12 euros per resident per day. This figure turns out to be below the savings suggested by a similar study carried out in a hospital environment where the authors suggest savings of around 4 euros per patient \[[@B9-pharmacy-08-00039]\]. Several factors could explain this difference: the prices of hospital medications are lower than those dispensed to outpatients since these prices are set after an invitation to tender for each active ingredient. Furthermore, the profiles of hospitalized patients and those residing in nursing homes and the sizes of the two samples are different. Finally, Pages et al. \[[@B9-pharmacy-08-00039]\] weighted the cost according to the length of hospital stay, whereas in our study the cost was estimated at time t.

Geriatric assessment of prescriptions has shown to be effective in improving the quality of life of patients and in reducing adverse events such as fall injuries and readmissions \[[@B25-pharmacy-08-00039]\].

The strengths of this study are the large sample size and the consideration of the socio-demographic characteristics and comorbidities of the study population. However, we limited our study to the direct cost of PIM and the estimated profit after their substitution without taking into account the overall cost generated by drug-induced iatrogenesis. In fact, one French study estimated the average cost of avoidable hospitalizations linked to iatrogenesis at 9500 euros \[[@B26-pharmacy-08-00039]\]. In the United States, hospital-related spending on drug-induced iatrogenesis is estimated to be approximately \$177 billion \[[@B27-pharmacy-08-00039],[@B28-pharmacy-08-00039]\]. In Europe the cost of hospitalizations for falls linked to benzodiazepines is estimated between 1.5 and 2.2 billion euros \[[@B28-pharmacy-08-00039]\]. Likewise, as mentioned above, we estimated the gross cost at time t, and the duration of exposure to PIM was not taken into account.

In conclusion, PIM are still frequently prescribed to the elderly in nursing homes and generate a significant cost. Deprescribing these drugs improves the quality of medication for this population and reduces the cost of prescriptions. More studies are needed to estimate the overall cost of exposure to PIM by taking into account the duration of exposure to PIM and the adverse drug reactions leading to hospitalization, which generates additional costs.
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###### 

Alternative drugs of PIM proposed by EU(7) PIM list.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  PIM                                      Alternatives                             PIM                                 Alternatives
  ---------------------------------------- ---------------------------------------- ----------------------------------- -------------------------
  aceclofenac                              paracetamol                              digoxin 0.5 mg                      digoxin 0.125 mg

  acenocoumarol                            warfarin                                 diltiazem                           diltiazem

  Acetylsalicylic acid/dipyridamole        Acetylsalicylic acid                     dipyridamole                        Acetylsalicylic acid

  alimemazine                              zopiclone 3.75 mg                        dipyridamole/Acetylsalicylic acid   Acetylsalicylic acid

  alprazolam                               oxazepam                                 Domperidone \> 30 mg/day            domperidone 10 mg

  amiodarone                               amiodarone                               dosulepine                          sertraline

  amitriptyline                            sertraline                               doxazosine                          tamsulosin

  aripiprazole                             risperidone                              escitalopram                        sertraline

  baclofen                                 baclofen                                 esomeprazole                        Stop

  bromazepam                               oxazepam                                 fesoterodine                        Stop

  carbamazepine                            carbamazepine                            flavoxate                           Stop

  chlorpromazine                           risperidone                              flecainide                          flecainide

  citalopram                               sertraline                               fluoxetine                          sertraline

  clidinium/chlordiazepoxide               clidinium/\                              flurbiprofen                        paracetamol
                                           chlordiazepoxide                                                             

  clobazam                                 oxazepam                                 fluvoxamine                         sertraline

  clomipramine                             sertraline                               glibenclamide                       glibenclamide

  clonazepam                               clonazepam                               glimepiride                         glimepiride

  clorazepate                              oxazepam                                 haloperidol                         risperidone

  clotiazepam                              clotiazepam                              hydroxyzine                         oxazepam

  clozapine                                clozapine                                ibuprofen                           paracetamol

  colchicine                               colchicine                               ibuprofen/codeine                   ibuprofen/codeine

  colchicine/opium                         colchicine/opium                         ivabradine                          ivabradine

  cyamemazine                              risperidone                              ketoprofen                          paracetamol

  diazepam                                 oxazepam                                 ketoprofen gel                      Stop

  diclofenac                               paracetamol                              labetalol                           bisoprolol

  diclofenac 1% gel                        stop                                     lansoprazole                        Stop

  diclofenac/misoprostol                   diclofenac/misoprostol                   levomepromazine                     risperidone

  loperamide                               phloroglucinol                           lithium                             lithium

  loprazolam                               zopiclone 3.75 mg                        prazepam                            oxazepam

  lorazepam                                lorazepam                                prazosin                            prazosin

  lormetazepam                             zopiclone 3.75 mg                        propericiazine                      risperidone

  maprotiline                              sertraline                               propranolol                         bisoprolol

  metformin/sitagliptine 1000 mg/50 mg     metformin/sitagliptine 1000 mg/50 mg     rabeprazole                         Stop

  metformine/vildagliptine 1000 mg/50 mg   metformine/vildagliptine 1000 mg/50 mg   racecadotril                        phloroglucinol

  metoclopramide                           domperidone                              ranitidine                          Stop

  metopimazine                             domperidone                              rilmenidine                         rilmenidine

  moxonidine                               Stop                                     risperidone                         risperidone

  naftidrofuryl                            Stop                                     ropinirole                          ropinirole

  naproxen                                 naproxen                                 rotigotine                          rotigotine

  nicardipine                              nicardipine                              scopolamine                         domperidone

  nifedipine                               nifedipine                               sitagliptine                        sitagliptine

  nitrazepam                               zopiclone 3.75 mg                        sitagliptine/metformin              sitagliptine/metformin

  nordazepam                               oxazepam                                 solifenacin                         Stop

  olanzapine \> 10 mg/j                    olanzapine 5 mg                          sotalol                             bisoprolol

  omeprazole                               Stop                                     spironolactone                      spironolactone

  oxazepam \> 60 mg/j                      oxazepam \< 50 mg                        spironolactone/altizide             spironolactone/altizide

  oxybutynine                              Stop                                     sulindac                            Stop

  pantoprazole                             Stop                                     terazosine                          tamsulosin

  paracetamol/codeine                      paracetamol/codeine                      tramadol                            tramadol

  paroxetine                               sertraline                               tramadol/paracetamol                tramadol/paracetamol

  phenobarbital                            phenobarbital                            trihexyphenidyl                     Stop

  pimozide                                 risperidone                              trimebutine                         Stop

  pinaverium                               Stop                                     tropatepine                         tropatepine

  pindolol                                 bisoprolol                               trospium                            Stop

  pipotiazine                              risperidone                              venlafaxine                         venlafaxine

  piracetam                                piracetam                                verapamil                           verapamil

  piribedil                                piribedil                                verapamil/trandolapril              verapamil/trandolapril

  piroxicam                                piroxicam                                vildagliptine                       vildagliptine

  pramipexole                              pramipexole                              vildagliptine/metformin             vildagliptine/metformin

  zolpidem 10mg \> 5 mg/j                  zolpidem 10 mg                                                               

  zopiclone 7.5 mg                         zopiclone 3.75 mg                                                            

  zuclopenthixol                           risperidone                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------

![Study flow chart.](pharmacy-08-00039-g001){#pharmacy-08-00039-f001}

![Comparison of the mean cost of prescriptions according to the presence or absence of potentially inappropriate medications.](pharmacy-08-00039-g002){#pharmacy-08-00039-f002}

![Comparison of total prescription cost between initial and substituted prescriptions (red) and comparison of cost between PIM and alternatives drugs (green).](pharmacy-08-00039-g003){#pharmacy-08-00039-f003}

pharmacy-08-00039-t001_Table 1

###### 

Characteristics of the study population.

  Characteristics of Residents           Total            Residents with at Least One PIM   Residents without PIM
  -------------------------------------- ---------------- --------------------------------- -----------------------
  Number of residents                    1240             959                               281
  Age, mean \[± SD\]                     87.76 \[±7.6\]   87.36 \[±7.7\]                    89.12 \[±6.9\]
  Sex (%)                                                                                   
  Female                                 948 (76.5%)      732 (76.3%)                       216 (76.9%)
  Male                                   292 (23.6%)      227 (23.7%)                       65 (23.1%)
  IRG (%)                                                                                   
  1--2                                   532 (42.9%)      411 (42.9%)                       121 (43.1%)
  3--4                                   298 (24%)        229 (23.9%)                       69 (24.6%)
  5--6                                   57 (4.6%)        42 (4.4%)                         15 (5.3%)
  Number of medications, mean \[± SD\]   6.26 \[±2.9\]    6.91 \[±2.7\]                     4.07 \[±2.2\]
  Number of medications 0--4             367 (29.6%)      196 (20.4%)                       171 (60.9%)
  Number of medications 5--9             721 (58.1%)      614 (64%)                         107 (38.1%)
  Number of medications \>9              152 (12.3%)      149 (15.5%)                       3 (1.1%)
  Charlson index                                                                            
  0                                      0                0                                 0
  1--2                                   22 (2%)          16 (2%)                           6 (2%)
  3--4                                   249 (20%)        214 (22%)                         35 (12%)
  ≥5                                     969 (78%)        729 (76%)                         240 (85%)
  Number of PIM, mean \[±SD\]            1.58 \[±1.3\]    2.04 \[±1.2\]                     0

PIM: Potentially Inappropriate Medication; SD: standard deviation; IRG: Iso-Resource Group.

pharmacy-08-00039-t002_Table 2

###### 

Frequency of pathology of the study population.

  Pathologies               Number of Patients
  ------------------------- --------------------
  Neuropsychiatric          863 (32%)
  Dementia                  380 (14%)
  Depression                245 (9%)
  Cerebrovascular disease   103 (4%)
  Cardiovascular diseases   763 (28%)
  Hypertension              462 (17%)
  Atrial fibrillation       135 (5%)
  Heart failure             79 (3%)
  Metabolic diseases        308 (11%)
  Thyroid disease           152 (6%)
  Diabetes                  125 (5%)
  Inflammatory bowel        194 (7%)
  Ulcer                     98 (4%)
  Malnutrition              50 (2%)
  Osteoarticular diseases   173 (6%)
  Arthrosis                 89 (3%)
  Osteoporosis              68 (3%)
  Hematology and oncology   140 (5%)
  Cancer                    90 (3%)
  Renal failure             72 (3%)
